Articles tagged with Adjuvants
A new review suggests that immune checkpoint inhibitors can help selected patients with hepatocellular carcinoma (HCC) shrink or stabilize tumors before transplantation, increasing transplant eligibility. However, the therapy also carries a risk of rejection, highlighting the need for precise timing and patient selection.
The new vaccine adjuvant induces a strong mucosal immune response in the GI tract, which is crucial for eradicating polio. The researchers achieved a 20-fold increase in antibodies needed for mucosal immunity compared to the existing injectable polio vaccine.
The study found that adjuvant nivolumab did not improve disease-free survival in patients with resected non–small cell lung cancer. The treatment was also not effective in sensitizing EGFR and ALK alterations.
A new COVID-19 vaccine adjuvant has been developed that can extend vaccine protection for up to two years, reducing the need for repeated boosters. The adjuvant, known as mannadjuvant, was created from a fungal component and showed a more pronounced response against omicron viral components than the vaccine alone.
Researchers at the Wyss Institute developed DoriVac, a DNA nanotechnology-enabled vaccine platform that induces broad immunity against infectious viruses, including SARS-CoV-2, HIV, and Ebola. The platform produces potent antigen-specific immune responses and is more stable and easier to manufacture than traditional vaccine platforms.
Researchers found that plant phenolic acids can dramatically boost the activity of existing antibiotics against multidrug resistant E. coli, reducing the chance of new resistance emerging. The compounds also make it easier for antibiotics to enter and stay inside bacterial cells.
The R21/Matrix-M malaria vaccine generates nearly identical antibodies to those following a natural infection, providing strong protection against the earliest life stage of malaria parasites. This long-lasting immunity is effective without requiring further adaptation.
A study by Georgia State University researchers found that a novel mucosal adjuvant enhances protection against various influenza virus challenges. The adjuvant, derived from mature bone marrow-derived dendritic cells, elicited significant and cross-reactive immune responses in mice.
A new dual-phase CT AI tool, NeoPred, combines pre-treatment and pre-surgery scans with clinical data to predict major pathological response in NSCLC patients. The model achieved high accuracy rates, including AUCs of 0.772-0.787, outperforming surgeons and improving diagnostic accuracy.
A two-part delivery strategy combining adjuvants improves antibody responses and follicular buildup of HIV protein in mouse model, offering new hope for effective HIV vaccine. The dual-adjuvant approach yields stronger and more potent immune responses than individual adjuvants alone.
Researchers at Terasaki Institute develop lipopeptide hydrogels to deliver peptide-based cancer vaccines, demonstrating sustained release and enhanced immune cell uptake. The system shows promise in overcoming limitations of traditional peptide-based vaccines.
The phase 3 KATHERINE clinical trial found trastuzumab emtansine to be an effective adjuvant treatment for high-risk HER2-positive breast cancer patients, reducing the risk of death or invasive disease by 46% and improving survival. The study showed consistent benefits across patient subgroups, supporting T-DM1 as a new standard of care.
Researchers developed a new system, MEMPHIS, that models mRNA vaccine responses in a dish, providing insight into vaccine activity in vulnerable populations. The study found muted innate immune responses in people over age 60, indicating an impaired ability to support Th1 immunity.
Researchers developed a nasal vaccine combining traditional pertussis antigens with an innovative adjuvant called T-vant to boost immune response. The new vaccine was shown to prevent the bacteria's colonization in the respiratory tract, significantly curbing whooping cough spread.
The development of vaccine adjuvants has evolved significantly, shifting from empirical methods to a more structured approach grounded in rational drug design. This new era emphasizes the importance of understanding structural and functional traits of adjuvants.
Researchers at Stanford University developed a nanoparticle platform to make vaccines more effective against various pathogens. The platform allows for the elicitation of different immune responses, enabling the identification of the most effective type of protection.
Despite promising results, adjuvant therapies face challenges due to a lack of universally accepted standards for treatment protocols. Future research should aim to refine patient selection criteria to maximize efficacy and minimize harm.
A new study has identified specific RNAs that may help identify stage II colon cancer patients who are likely to benefit from chemotherapy following surgery. The researchers found that certain housekeeping RNAs were up-regulated in patients with recurrence, suggesting their potential role in the metastatic process.
Researchers identify key factors that determine when melanoma metastasizes, shedding light on optimal treatment strategies. Understanding tumor doubling time and risk assessment can help clinicians select high-risk patients who may benefit from adjuvant systemic therapy.
Researchers at the University of Würzburg have discovered a natural substance that can inhibit vitamin B6 degradation, increasing its levels in nerve cells involved in learning and memory processes. This compound, 7,8-Dihydroxyflavone, has been linked to improved spatial learning and memory capacity in mice.
Researchers review Silibinin's efficacy in managing inflammation, a key factor in tumour development and aging. The molecule may reduce drug-related toxicity and increase therapeutic potential in integrated cancer therapies.
Researchers have identified a promising new vaccine adjuvant called C100, derived from chitin, which stimulates key sensing and signalling molecules to regulate anti-tumour immune responses. The discovery offers hope for developing effective adjuvants for in situ vaccines in cancer immunotherapy.
Researchers at the University of California, Berkeley, have successfully produced the QS-21 adjuvant in yeast, which is currently extracted from tree bark. The production process is cheaper and more environmentally friendly than traditional methods, making it a promising solution for lowering vaccine costs and increasing availability.
A randomized clinical trial of 3,020 patients with high-risk nonmetastatic breast cancer found daily aspirin therapy had no effect on breast cancer recurrence or survival in early follow-up. Aspirin should not be recommended as an adjuvant breast cancer treatment despite its potential benefits and wide availability
A phase 3 trial shows that pembrolizumab significantly prolongs overall survival in high-risk kidney cancer patients. The treatment delays recurrences and helps patients live longer, with a 38% reduction in risk of death compared to placebo.
New data show that adding pembrolizumab to chemotherapy before and after surgery for breast cancer leads to better outcomes, with significant increases in pathological complete response rates across all age groups. The study also found similar rates of breast-conserving surgery and mastectomy, as well as lower residual cancer burdens.
A new DNA origami platform, DoriVac, enables precise spacing of adjuvant molecules and a variety of antigens to enhance anti-tumor responses. The vaccine demonstrated enhanced efficacy in controlling tumor growth and prolonging survival in mice, synergizing with immune checkpoint inhibitors.
The Access to Advanced Health Institute (AAHI) has received $12.7 million to develop a novel immune-stimulating adjuvant formulation, NanoAlum, which aims to improve vaccine protection against complex diseases like tuberculosis and influenza.
Researchers at MIT have developed a new type of nanoparticle that can both deliver vaccines and act as an adjuvant to generate a strong immune response. The particles, called metal-organic frameworks (MOFs), were shown to be effective in delivering the SARS-CoV-2 spike protein and boosting the immune system's response.
A new study aims to enhance and prolong vaccine effectiveness by delivering adjuvants to white blood cells using lipid nanoparticles. The research, led by WVU professor Sharan Bobbala, has the potential to provide broader protection against evolving viruses and multiple diseases.
Researchers identify a promising prognostic biomarker for lung cancer using circulating tumor DNA-based minimal residual disease detection. The study found that this method can effectively guide treatment decisions and predict recurrence risk, potentially modifying the lung cancer treatment paradigm.
Korea University researchers found that perioperative radiotherapy significantly improves survival rates among HCC patients at high risk of recurrence. The study suggests that radiotherapy can reduce recurrence and improve survival in these patients, providing a significant adjuvant treatment option.
A large study of 432,000 cancer patients who underwent major surgery found an increased rate of venous thromboembolism associated with cancer surgery. The risk persisted for about two to four months postoperatively and varied between cancer types.
A phase 3 trial shows that adjuvant pembrolizumab therapy significantly prolongs overall survival in patients with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence. The treatment reduces the risk of death by 38% compared to placebo.
Scientists have successfully replicated QS-21, a potent vaccine adjuvant, in an alternative plant host for the first time. This breakthrough enables the production of this highly valued compound in a more sustainable manner.
Researchers from MD Anderson Cancer Center reported a case of a patient with an exceptional response to pazopanib treatment for over 5 years. The study shows that pazopanib prevents or delays the progression of additional metastasis in EWSR1-NFATC2 positive sarcomas. Further studies are warranted.
Researchers at Duke-NUS Medical School have discovered a potential intranasal vaccine candidate that provides improved, longer-lasting immunity against COVID-19. The vaccine boosts mucosal antibody response and enhances long-term immune protection through preferential induction of airway-resident T cells and central memory T cells.
A Mediterranean diet has been found to be a straightforward and effective approach for improving IVF success rates, with high intakes of fruits, vegetables, whole grains, and omega-3 fatty acids. The diet's benefits were seen in both embryo development and pregnancy outcomes, even after just six weeks of implementation.
Researchers found that pesticide-adjuvant combinations used in almond orchards can interfere with honey bee communication. The study suggests that these chemicals can alter the antennal responses to brood and alarm pheromones, potentially disrupting colony function.
A new study reveals a genetic vulnerability to the herbicide tolpyralate in nearly 50 sweet and field corn lines, with sensitivity increased by adjuvants commonly co-applied with HPPD-inhibitors. The source of the sugary enhancer gene is among the most sensitive genotypes, suggesting widespread potential.
A research team has introduced a spectrum of potential adjuvants, including α-GalCer analogs with improved activity. The new compounds trigger stronger immune responses in mice, with some demonstrating better adjuvant properties than previously optimized variants.
The Precision Vaccines Program at Boston Children's Hospital has been awarded a $9 million NIH contract to develop a small molecule adjuvant to enhance the effectiveness of flu vaccines. The collaboration with Inimmune aims to increase the body's immune response to vaccines and protect vulnerable populations.
Researchers developed a reliable and reproducible real-time live tissue sensitivity assay (RT-LTSA) using fresh tumor samples to predict patients' clinical response to chemotherapy. The study showed improved disease-free survival and reduced recurrence rates in patients who received RT-LTSA sensitive adjuvant regimens.
Researchers at the University of Montana are developing vaccines to prevent fentanyl and heroin drug overdoses. The first vaccine will target heroin, followed by a fentanyl vaccine in Phase I clinical trials. The vaccines aim to elicit antibodies against target opioids while sparing critical medications used in opioid addiction treatment.
A new study published in JNCCN found that the adoption of clinical research results led to a significant increase in the use of shorter adjuvant chemotherapy periods, with CAPOX becoming more widely used. The study also revealed disparities in treatment patterns, with Black patients being more likely to receive shorter chemotherapy reg...
A new adjuvanted intranasal vaccine has shown promise in protecting both young and old mice against SARS-CoV-2 infection. The vaccine combines an RNA-based molecule with a nanoemulsion, resulting in a strong immune response.
A team of researchers found that a hydrogen sulfide donor adjuvant can disrupt mitochondrial respiration, suppressing heat shock protein production and making tumor cells more sensitive to photothermal therapy. This approach led to the eradication of tumors in laboratory mice with breast tumors within just a few days.
Researchers discuss chemotherapeutic resistance in recurring ovarian cancer, focusing on the unfolded protein response and its effect on polyploid giant cancer cells. Understanding this mechanism could lead to investigating cancer cell molecular mechanisms and potential therapeutic strategies.
Researchers at the University of Chicago have found that adding small molecules called immunomodulators to vaccine adjuvants can regulate the body's response to vaccines, reducing negative side effects. The study increased antibody response in flu vaccine models and reduced inflammation in typhoid vaccine models.
Researchers have created two novel adjuvants that significantly enhance the immune response to vaccines. The new adjuvants target toll-like receptors and are designed to be tailored for every individual vaccine, potentially reducing side effects and increasing effectiveness.
Researchers have discovered a new pathway to produce saponin-based vaccine adjuvants using the genome of the Chilean soapbark tree. This breakthrough could lead to more potent and affordable vaccines, with potential applications in COVID-19, shingles, and malaria prevention.
A Phase 1 clinical trial of AAHI's thermostable, freeze-dried single-vial ID93 + GLA-SE vaccine candidate showed higher levels of antibodies and favorable cellular immune responses compared to the two-vial presentation. The results represent significant progress in global efforts to combat TB.
A phase 2 clinical trial shows that treating resectable stage 3 and 4 melanoma patients with pembrolizumab both before and after surgery greatly improves outcomes compared to pembrolizumab given only after surgery. This approach resulted in significantly longer event-free survival rates.
Patients with stage IIIB-IV melanoma who received neoadjuvant pembrolizumab had a significantly lower risk of cancer recurrence compared to those receiving adjuvant therapy only. The study found improved event-free survival rates in the neoadjuvant group, suggesting that starting immunotherapy before surgery generates better outcomes.
AAHI will develop a prototype nasal spray using its novel adjuvant formulation platform, promising to shorten timelines for emergency response to and mitigate impacts from biological threats. The project aims to create a temperature-stable and broadly protective nasal spray against multiple respiratory viruses.
Researchers investigated the effects of everolimus on the STAT3/HIF-1α/VEGF pathway in TP53 mutant cell lines and xenograft models. Everolimus treatment significantly inhibited cell growth and reduced tumor angiogenesis and lymphangiogenesis.
Researchers developed a new way to increase vaccine potency by changing the structural location of antigens and adjuvants. This approach, called 'rational vaccinology,' allows for precise dosing and tailored presentation of vaccine components, leading to improved immune response and cancer cell targeting.
A nationwide retrospective study showed that adjuvant chemotherapy after neo-adjuvant chemotherapy and surgery significantly improved overall survival in patients with pancreatic adenocarcinoma, regardless of lymph node status or resection margins. The study included nearly 900 patients and was published in JAMA Oncology.
A follow-up study found that the 2-dose vaccines still provided protection against lung disease one year after vaccination as infants. The adjuvanted protein vaccine candidate maintained higher levels of neutralizing antibodies and provided superior protection compared to the mRNA vaccine.
Researchers have found that experimental vaccines, including a protein-based vaccine candidate with an adjuvant, provide superior protection against lung disease and higher levels of neutralizing antibodies compared to mRNA vaccines. The results inform the optimization and development of COVID-19 vaccines for young infant populations.